Pavan Kasi Bendapudi, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Purpura, Thrombotic Thrombocytopenic | 11 | 2021 | 131 | 4.360 |
Why?
|
Thrombotic Microangiopathies | 8 | 2023 | 132 | 3.320 |
Why?
|
Purpura Fulminans | 4 | 2024 | 22 | 2.990 |
Why?
|
Plasma Exchange | 6 | 2021 | 152 | 1.930 |
Why?
|
Disseminated Intravascular Coagulation | 2 | 2022 | 188 | 0.930 |
Why?
|
Ursidae | 1 | 2023 | 26 | 0.920 |
Why?
|
Erythroblastosis, Fetal | 1 | 2023 | 60 | 0.920 |
Why?
|
Hematologic Diseases | 2 | 2023 | 498 | 0.880 |
Why?
|
Thrombosis | 10 | 2023 | 2968 | 0.840 |
Why?
|
Neisseria meningitidis, Serogroup C | 1 | 2021 | 11 | 0.800 |
Why?
|
Protein C | 2 | 2018 | 138 | 0.790 |
Why?
|
Factor V Deficiency | 1 | 2021 | 13 | 0.790 |
Why?
|
Meningococcal Infections | 1 | 2021 | 77 | 0.760 |
Why?
|
Factor XII | 1 | 2020 | 19 | 0.760 |
Why?
|
Thrombomodulin | 1 | 2018 | 102 | 0.630 |
Why?
|
Venous Thrombosis | 2 | 2023 | 1239 | 0.580 |
Why?
|
Hemostasis | 2 | 2017 | 458 | 0.530 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2019 | 233 | 0.510 |
Why?
|
ADAM Proteins | 1 | 2015 | 243 | 0.470 |
Why?
|
Blood Coagulation | 5 | 2023 | 1127 | 0.470 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1681 | 0.450 |
Why?
|
Sepsis | 2 | 2024 | 2593 | 0.410 |
Why?
|
Protein Disulfide-Isomerases | 3 | 2018 | 198 | 0.390 |
Why?
|
Immunologic Factors | 1 | 2019 | 1580 | 0.350 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.340 |
Why?
|
HSP47 Heat-Shock Proteins | 1 | 2023 | 4 | 0.240 |
Why?
|
Hemagglutinins | 1 | 2023 | 117 | 0.230 |
Why?
|
Receptors, Complement | 1 | 2024 | 264 | 0.230 |
Why?
|
Erythrocytes, Abnormal | 1 | 2023 | 125 | 0.220 |
Why?
|
Blood Group Incompatibility | 1 | 2023 | 146 | 0.220 |
Why?
|
Anticoagulants | 5 | 2022 | 4599 | 0.210 |
Why?
|
Angioedemas, Hereditary | 1 | 2023 | 91 | 0.210 |
Why?
|
Hemorrhage | 4 | 2022 | 3461 | 0.210 |
Why?
|
Hemolysis | 1 | 2023 | 420 | 0.200 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2021 | 43 | 0.200 |
Why?
|
ABO Blood-Group System | 1 | 2023 | 367 | 0.200 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15540 | 0.190 |
Why?
|
Urogenital Abnormalities | 1 | 2023 | 261 | 0.190 |
Why?
|
Humans | 40 | 2024 | 744343 | 0.180 |
Why?
|
Urinary Tract | 1 | 2023 | 309 | 0.180 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2021 | 142 | 0.180 |
Why?
|
Lasers | 2 | 2021 | 952 | 0.180 |
Why?
|
Capnocytophaga | 1 | 2018 | 26 | 0.170 |
Why?
|
Abruptio Placentae | 1 | 2020 | 118 | 0.170 |
Why?
|
Blood Coagulation Factors | 1 | 2021 | 355 | 0.160 |
Why?
|
Shock | 1 | 2021 | 318 | 0.160 |
Why?
|
Multiple Organ Failure | 1 | 2021 | 390 | 0.160 |
Why?
|
Factor XI Deficiency | 1 | 2018 | 18 | 0.160 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2020 | 183 | 0.160 |
Why?
|
Protein C Deficiency | 1 | 2017 | 29 | 0.160 |
Why?
|
Cohort Studies | 6 | 2024 | 40561 | 0.160 |
Why?
|
Cisplatin | 1 | 2024 | 1662 | 0.150 |
Why?
|
Genes, myc | 2 | 2008 | 399 | 0.150 |
Why?
|
Blood Platelets | 4 | 2020 | 2508 | 0.140 |
Why?
|
Platelet Aggregation | 2 | 2018 | 798 | 0.140 |
Why?
|
Vasculitis | 1 | 2021 | 519 | 0.140 |
Why?
|
Models, Economic | 1 | 2021 | 713 | 0.140 |
Why?
|
Endothelial Cells | 2 | 2020 | 3479 | 0.140 |
Why?
|
E-Selectin | 1 | 2018 | 579 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.140 |
Why?
|
Zinc | 1 | 2020 | 684 | 0.140 |
Why?
|
Endothelium | 1 | 2018 | 778 | 0.140 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 954 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1184 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1179 | 0.120 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4560 | 0.120 |
Why?
|
Titanium | 1 | 2017 | 494 | 0.120 |
Why?
|
Adult | 14 | 2024 | 214055 | 0.120 |
Why?
|
Male | 16 | 2021 | 350118 | 0.110 |
Why?
|
Oncogenes | 2 | 2011 | 1265 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2021 | 12959 | 0.110 |
Why?
|
Aortic Aneurysm | 1 | 2018 | 643 | 0.110 |
Why?
|
Protein Folding | 1 | 2016 | 843 | 0.110 |
Why?
|
Macaca mulatta | 2 | 2017 | 2375 | 0.110 |
Why?
|
Gene Silencing | 2 | 2008 | 1538 | 0.100 |
Why?
|
Fibrin Fibrinogen Degradation Products | 3 | 2020 | 426 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2021 | 5391 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1972 | 0.100 |
Why?
|
Fibrinolytic Agents | 1 | 2021 | 2158 | 0.100 |
Why?
|
Recurrence | 2 | 2021 | 8340 | 0.090 |
Why?
|
Middle Aged | 11 | 2024 | 213383 | 0.090 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6895 | 0.090 |
Why?
|
Endoplasmic Reticulum | 1 | 2016 | 1144 | 0.090 |
Why?
|
Perioperative Care | 1 | 2018 | 1002 | 0.090 |
Why?
|
Heparin | 1 | 2017 | 1637 | 0.090 |
Why?
|
Animals | 14 | 2023 | 168757 | 0.090 |
Why?
|
Aorta | 1 | 2018 | 2061 | 0.090 |
Why?
|
Nitric Oxide | 1 | 2018 | 2132 | 0.090 |
Why?
|
Female | 13 | 2023 | 380194 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1387 | 0.090 |
Why?
|
Propensity Score | 1 | 2016 | 1781 | 0.090 |
Why?
|
Acute Disease | 1 | 2020 | 7149 | 0.090 |
Why?
|
Bacterial Infections | 1 | 2017 | 1401 | 0.080 |
Why?
|
Aged | 8 | 2021 | 163280 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3870 | 0.080 |
Why?
|
Thrombin | 2 | 2023 | 598 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.080 |
Why?
|
Software | 1 | 2022 | 4443 | 0.080 |
Why?
|
Reoperation | 1 | 2018 | 4201 | 0.080 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2018 | 1390 | 0.080 |
Why?
|
Epilepsy | 1 | 2023 | 3310 | 0.080 |
Why?
|
Mice | 10 | 2023 | 81183 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.080 |
Why?
|
Electrocardiography | 1 | 2021 | 6442 | 0.080 |
Why?
|
Plasma | 2 | 2022 | 575 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2024 | 77449 | 0.070 |
Why?
|
Length of Stay | 2 | 2021 | 6309 | 0.070 |
Why?
|
Genomics | 1 | 2022 | 5720 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3523 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8949 | 0.070 |
Why?
|
Prospective Studies | 2 | 2024 | 53288 | 0.070 |
Why?
|
Farnesol | 1 | 2005 | 20 | 0.070 |
Why?
|
Fluorine Radioisotopes | 1 | 2008 | 442 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2016 | 3798 | 0.070 |
Why?
|
Genes, ras | 1 | 2008 | 690 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5442 | 0.060 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 565 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12354 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2011 | 987 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2018 | 6622 | 0.060 |
Why?
|
Prognosis | 3 | 2023 | 29063 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2023 | 25625 | 0.060 |
Why?
|
Lymphoma | 2 | 2011 | 1877 | 0.060 |
Why?
|
Osteosarcoma | 1 | 2008 | 881 | 0.060 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2023 | 97 | 0.050 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2023 | 143 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2019 | 63114 | 0.050 |
Why?
|
Cell Shape | 1 | 2023 | 375 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2023 | 964 | 0.050 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13102 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Blood Component Transfusion | 1 | 2022 | 143 | 0.050 |
Why?
|
Models, Biological | 2 | 2017 | 9583 | 0.050 |
Why?
|
Penetrance | 1 | 2023 | 381 | 0.050 |
Why?
|
Database Management Systems | 1 | 2022 | 270 | 0.050 |
Why?
|
Risk Factors | 4 | 2024 | 72290 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2008 | 2016 | 0.040 |
Why?
|
ras Proteins | 1 | 2005 | 1060 | 0.040 |
Why?
|
Arterioles | 1 | 2020 | 254 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2023 | 795 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 343 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3589 | 0.040 |
Why?
|
von Willebrand Factor | 1 | 2023 | 669 | 0.040 |
Why?
|
Decision Trees | 1 | 2021 | 506 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 631 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1919 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 1363 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 881 | 0.040 |
Why?
|
Fibrin | 1 | 2020 | 506 | 0.040 |
Why?
|
Computer Simulation | 1 | 2011 | 6196 | 0.040 |
Why?
|
Abdominal Muscles | 1 | 2018 | 166 | 0.040 |
Why?
|
Bone and Bones | 1 | 2008 | 2575 | 0.040 |
Why?
|
Neoplasms | 2 | 2022 | 21683 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 56430 | 0.040 |
Why?
|
Factor Xa | 1 | 2018 | 162 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 781 | 0.040 |
Why?
|
Mice, Inbred C57BL | 3 | 2023 | 21827 | 0.040 |
Why?
|
Markov Chains | 1 | 2021 | 969 | 0.040 |
Why?
|
Factor VIIa | 1 | 2018 | 101 | 0.040 |
Why?
|
Sulfhydryl Compounds | 1 | 2018 | 298 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 841 | 0.040 |
Why?
|
Sternotomy | 1 | 2018 | 121 | 0.040 |
Why?
|
Antithrombin III | 1 | 2017 | 128 | 0.040 |
Why?
|
Alloys | 1 | 2017 | 122 | 0.040 |
Why?
|
Sarcoma | 1 | 2008 | 1897 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2008 | 2529 | 0.030 |
Why?
|
Mice, Transgenic | 4 | 2011 | 9734 | 0.030 |
Why?
|
P-Selectin | 1 | 2018 | 600 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 1677 | 0.030 |
Why?
|
Infant | 1 | 2017 | 35136 | 0.030 |
Why?
|
Integrin beta3 | 1 | 2015 | 122 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2022 | 1783 | 0.030 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 407 | 0.030 |
Why?
|
Allosteric Regulation | 1 | 2016 | 408 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1788 | 0.030 |
Why?
|
Child, Preschool | 1 | 2017 | 41006 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2008 | 8428 | 0.030 |
Why?
|
Platelet Activation | 1 | 2018 | 673 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2023 | 19905 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2007 | 3703 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2016 | 698 | 0.030 |
Why?
|
Protein Binding | 2 | 2016 | 9386 | 0.030 |
Why?
|
Adolescent | 2 | 2021 | 85781 | 0.030 |
Why?
|
Drug Costs | 1 | 2021 | 1105 | 0.030 |
Why?
|
Autoantibodies | 1 | 2021 | 2035 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1855 | 0.030 |
Why?
|
Skull | 1 | 2017 | 813 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1660 | 0.030 |
Why?
|
Disease Models, Animal | 4 | 2016 | 18029 | 0.020 |
Why?
|
Cesarean Section | 1 | 2020 | 1365 | 0.020 |
Why?
|
Placenta | 1 | 2020 | 1698 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1375 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6364 | 0.020 |
Why?
|
Computational Biology | 1 | 2022 | 3521 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2187 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2008 | 9239 | 0.020 |
Why?
|
Child | 1 | 2017 | 77709 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2016 | 3846 | 0.020 |
Why?
|
Models, Animal | 1 | 2016 | 2171 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
Cell Membrane | 1 | 2018 | 3748 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Iron | 1 | 2017 | 1774 | 0.020 |
Why?
|
Reference Values | 1 | 2016 | 4982 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2017 | 1736 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4149 | 0.020 |
Why?
|
Aortic Valve | 1 | 2018 | 1922 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7186 | 0.020 |
Why?
|
Hepatitis C | 1 | 2018 | 1591 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1536 | 0.020 |
Why?
|
Doxycycline | 1 | 2008 | 326 | 0.020 |
Why?
|
Bone Development | 1 | 2008 | 483 | 0.020 |
Why?
|
Salicylates | 1 | 2005 | 126 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 1356 | 0.020 |
Why?
|
Respiratory Mucosa | 1 | 2008 | 427 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2008 | 767 | 0.010 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1692 | 0.010 |
Why?
|
California | 1 | 2008 | 1402 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5179 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6314 | 0.010 |
Why?
|
Cell Proliferation | 2 | 2011 | 10481 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2008 | 1770 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 23338 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6171 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9146 | 0.010 |
Why?
|
Insulin | 1 | 2016 | 6580 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4568 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 3616 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 57776 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 29144 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 7023 | 0.010 |
Why?
|
Neuroblastoma | 1 | 2005 | 1226 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12951 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9727 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.010 |
Why?
|
Survival Analysis | 1 | 2008 | 10252 | 0.010 |
Why?
|
Survival Rate | 1 | 2008 | 12788 | 0.010 |
Why?
|
United States | 1 | 2021 | 69872 | 0.010 |
Why?
|
Signal Transduction | 2 | 2007 | 23403 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6234 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2008 | 11483 | 0.010 |
Why?
|
Incidence | 1 | 2008 | 20947 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16689 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13695 | 0.000 |
Why?
|